EICHORPublic-registry site landscape for NCT06923228, “A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis”, a Atopic Dermatitis (AD) study sponsored by CAGE Bio Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06923228 (registry record) |
| Study title | A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis |
| Official title | A Single-Blind, Prospective Clinical Study to Assess the Efficacy, Safety and Tolerability of CGB-500 1% Tofacitinib Ointment vs. an Active Comparator for Atopic Dermatitis |
| Sponsor | CAGE Bio Inc. |
| Condition(s) | Atopic Dermatitis (AD) |
| Phase | PHASE2 |
| Listed sites | 1 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06923228.
Eichor generates a preliminary site-risk snapshot for NCT06923228 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
